Jul. 27, 2022
apararenone
oral nonsteroidal MR antagonist Ph. II candidate in DN and NASH (discontinued) previous literature and hypothesis-driven opt. J. Med. Chem. Mitsubishi Tanabe Pharma Corporation, Yokohama, JP
oral nonsteroidal MR antagonist Ph. II candidate in DN and NASH (discontinued) previous literature and hypothesis-driven opt. J. Med. Chem. Mitsubishi Tanabe Pharma Corporation, Yokohama, JP